Rockwell Medical, Inc. (NASDAQ:RMTI) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.

RMTI has been the topic of several other reports. ValuEngine cut shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd. Zacks Investment Research upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and one has issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $7.50.

Rockwell Medical (NASDAQ RMTI) opened at 6.37 on Friday. Rockwell Medical has a 12 month low of $3.55 and a 12 month high of $8.98. The firm’s 50-day moving average is $7.46 and its 200 day moving average is $6.88. The firm’s market capitalization is $331.60 million.

Rockwell Medical (NASDAQ:RMTI) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by $0.04. The business had revenue of $13.24 million during the quarter, compared to the consensus estimate of $13.05 million. Rockwell Medical had a negative return on equity of 36.36% and a negative net margin of 36.35%. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the business posted ($0.11) earnings per share. On average, analysts expect that Rockwell Medical will post ($0.39) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.watchlistnews.com/rockwell-medical-inc-rmti-raised-to-sell-at-bidaskclub/1471507.html.

A number of hedge funds have recently bought and sold shares of RMTI. KCG Holdings Inc. purchased a new stake in Rockwell Medical during the first quarter valued at about $111,000. Geneva Advisors LLC boosted its stake in Rockwell Medical by 3.7% in the first quarter. Geneva Advisors LLC now owns 20,970 shares of the company’s stock valued at $131,000 after buying an additional 750 shares in the last quarter. Private Advisor Group LLC purchased a new stake in Rockwell Medical during the second quarter valued at about $182,000. American International Group Inc. boosted its stake in Rockwell Medical by 7.1% in the first quarter. American International Group Inc. now owns 29,509 shares of the company’s stock valued at $185,000 after buying an additional 1,955 shares in the last quarter. Finally, Cutter & CO Brokerage Inc. boosted its stake in Rockwell Medical by 6.3% in the second quarter. Cutter & CO Brokerage Inc. now owns 25,325 shares of the company’s stock valued at $201,000 after buying an additional 1,500 shares in the last quarter. Institutional investors and hedge funds own 20.54% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.